Ken Griffin Glaukos Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$113.62 - $135.39 $147,706 - $176,006	1,300 Added 6.99%	19,900 $2.59 Million
Q2 2024 Aug 14, 2024	BUY	$89.48 - $118.35 $742,684 - $982,305	8,300 Added 80.58%	18,600 $2.2 Million
Q1 2024 May 15, 2024	SELL	$76.4 - $96.33 $748,720 - $944,034	-9,800 Reduced 48.76%	10,300 $971,000
Q4 2023 Feb 14, 2024	BUY	$59.53 - $85.11 $500,052 - $714,924	8,400 Added 71.79%	20,100 $1.6 Million
Q3 2023 Nov 14, 2023	BUY	$69.23 - $79.09 $332,304 - $379,632	4,800 Added 69.57%	11,700 $880,000
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $31,808 - $49,846	700 Added 11.29%	6,900 $491,000
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $131,640 - $157,440	3,000 Added 93.75%	6,200 $310,000
Q4 2022 Feb 14, 2023	SELL	$40.82 - $57.75 $489,840 - $693,000	-12,000 Reduced 78.95%	3,200 $139,000
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $384,088 - $479,618	8,200 Added 117.14%	15,200 $809,000

340

47.1M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.73B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.